{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:53:12Z","timestamp":1794502392968,"version":"4.9.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-002092"],"award-info":[{"award-number":["INV-002092"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-004302"],"award-info":[{"award-number":["INV-004302"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A recent WHO recommendation for perennial malaria chemoprevention (PMC) encourages countries to adapt dose timing and number to local conditions. However, knowledge gaps on the epidemiological impact of PMC and possible combination with the malaria vaccine RTS,S hinder informed policy decisions in countries where malaria burden in young children remains high.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The EMOD malaria model was used to predict the impact of PMC with and without RTS,S on clinical and severe malaria cases in children under the age of two years (U2). PMC and RTS,S effect sizes were fit to trial data. PMC was simulated with three to seven doses (PMC-3-7) before the age of eighteen months and RTS,S with three doses, shown to be effective at nine months. Simulations were run for transmission intensities of one to 128 infectious bites per person per year, corresponding to incidences of &lt;\u20091 to 5500 cases per 1000 population U2. Intervention coverage was either set to 80% or based on 2018 household survey data for Southern Nigeria as a sample use case. The protective efficacy (PE) for clinical and severe cases in children U2 was calculated in comparison to no PMC and no RTS,S.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The projected impact of PMC or RTS,S was greater at moderate to high transmission than at low or very high transmission. Across the simulated transmission levels, PE estimates of PMC-3 at 80% coverage ranged from 5.7 to 8.8% for clinical, and from 6.1 to 13.6% for severe malaria (PE of RTS,S 10\u201332% and 24.6\u201327.5% for clinical and severe malaria, respectively. In children U2, PMC with seven doses nearly averted as many cases as RTS,S, while the combination of both was more impactful than either intervention alone. When operational coverage, as seen in Southern Nigeria, increased to a hypothetical target of 80%, cases were reduced beyond the relative increase in coverage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PMC can substantially reduce clinical and severe cases in the first two years of life in areas with high malaria burden and perennial transmission. A better understanding of the malaria risk profile by age in early childhood and on feasible coverage by age, is needed for selecting an appropriate PMC schedule in a given setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-023-04564-9","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T09:03:23Z","timestamp":1682327003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Perennial malaria chemoprevention with and without malaria vaccination to reduce malaria burden in young children: a modelling analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Manuela","family":"Runge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Stahlfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kok Ben","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semiu","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omowunmi F.","family":"Omoniwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin A.","family":"Bever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olusola","family":"Oresanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perpetua","family":"Uhomoibhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Galatas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Tibenderana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaline","family":"Gerardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"4564_CR1","volume-title":"World malaria report 2022","author":"WHO","year":"2022","unstructured":"WHO. World malaria report 2022. Geneva: World Health Organization; 2022."},{"key":"4564_CR2","volume-title":"World malaria report 2021","author":"WHO","year":"2021","unstructured":"WHO. World malaria report 2021. Geneva: World Health Organization; 2021."},{"key":"4564_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12936-021-03615-3","volume":"20","author":"M Lahuerta","year":"2021","unstructured":"Lahuerta M, Sutton R, Mansaray A, Eleeza O, Gleason B, Akinjeji A, et al. Evaluation of health system readiness and coverage of intermittent preventive treatment of malaria in infants (IPTi) in Kambia district to inform national scale-up in Sierra Leone. Malar J. 2021;20:74.","journal-title":"Malar J"},{"key":"4564_CR4","volume-title":"Guidelines for malaria","author":"WHO","year":"2021","unstructured":"WHO. Guidelines for malaria. Geneva: World Health Organization; 2021. (WHO\/UCN\/GMP\/2021.01)."},{"key":"4564_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1475-2875-4-33","volume":"4","author":"WP O\u2019Meara","year":"2005","unstructured":"O\u2019Meara WP, Breman JG, McKenzie FE. The promise and potential challenges of intermittent preventive treatment for malaria in infants (IPTi). Malar J. 2005;4:33.","journal-title":"Malar J"},{"key":"4564_CR6","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/S0140-6736(09)61258-7","volume":"374","author":"JJ Aponte","year":"2009","unstructured":"Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in african infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet. 2009;374:1533\u201342.","journal-title":"Lancet"},{"key":"4564_CR7","first-page":"CD011525","volume":"7","author":"EB Esu","year":"2021","unstructured":"Esu EB, Oringanje C, Meremikwu MM. Intermittent preventive treatment for malaria in infants. Cochrane Database Syst Rev. 2021;7:CD011525.","journal-title":"Cochrane Database Syst Rev"},{"key":"4564_CR8","unstructured":"WHO. Policy recommendation on intermittent preventive treatment during infancy with sulphadoxine-pyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa. Geneva, World Health Organization; 2010."},{"key":"4564_CR9","doi-asserted-by":"publisher","first-page":"e1385","DOI":"10.1016\/S2214-109X(22)00334-5","volume":"10","author":"C Menendez","year":"2022","unstructured":"Menendez C, Saute F, Greenwood B, Schellenberg D, Snow R, Alonso PL. Avoiding another lost decade in reducing malaria burden in african infants and young children. Lancet Glob Health. 2022;10:e1385\u201386.","journal-title":"Lancet Glob Health"},{"key":"4564_CR10","unstructured":"Carlin O. IPTi: the key to malaria reduction in Nigeria?. Malaria Consortium; 16 Nov 2021. https:\/\/www.malariaconsortium.org\/blog\/ipti-the-key-to-malaria-reduction-in-nigeria. Accessed 22 Feb 2022."},{"key":"4564_CR11","unstructured":"IS Global. Multiply: preventing malaria in early childhood. 2020. https:\/\/multiplyipti.net\/. Accessed 25 May 2022."},{"key":"4564_CR12","unstructured":"WHO recommends groundbreaking malaria vaccine for children at risk. Geneva, World Health Organization., ; 2021. https:\/\/www.who.int\/news\/item\/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk. Accessed 6 Oct 2021."},{"key":"4564_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS,S Clinical Trials Partnership","year":"2015","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31\u201345.","journal-title":"Lancet"},{"key":"4564_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12936-021-03888-8","volume":"20","author":"B Greenwood","year":"2021","unstructured":"Greenwood B, Cairns M, Chaponda M, Chico RM, Dicko A, Ouedraogo J-B, et al. Combining malaria vaccination with chemoprevention: a promising new approach to malaria control. Malar J. 2021;20:361.","journal-title":"Malar J"},{"key":"4564_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","volume":"385","author":"D Chandramohan","year":"2021","unstructured":"Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga R-S, Diarra M, et al. Seasonal malaria vaccination with or without seasonal malaria chemoprevention. N Engl J Med. 2021;385:1005\u201317.","journal-title":"N Engl J Med"},{"key":"4564_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s12936-021-03973-y","volume":"20","author":"K Galactionova","year":"2021","unstructured":"Galactionova K, Smith TA, Penny MA. Insights from modelling malaria vaccines for policy decisions: the focus on RTS,S. Malar J. 2021;20:439.","journal-title":"Malar J"},{"key":"4564_CR17","doi-asserted-by":"publisher","first-page":"e51773","DOI":"10.7554\/eLife.51773","volume":"9","author":"B Gao","year":"2020","unstructured":"Gao B, Saralamba S, Lubell Y, White LJ, Dondorp AM, Aguas R. Determinants of MDA impact and designing MDAs towards malaria elimination. eLife. 2020;9:e51773.","journal-title":"eLife"},{"key":"4564_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(19)30633-4","volume":"20","author":"HC Slater","year":"2020","unstructured":"Slater HC, Foy BD, Kobylinski K, Chaccour C, Watson OJ, Hellewell J, et al. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. Lancet Infect Dis. 2020;20:498\u2013508.","journal-title":"Lancet Infect Dis"},{"key":"4564_CR19","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1371\/journal.pone.0002661","volume":"3","author":"A Ross","year":"2008","unstructured":"Ross A, Penny M, Maire N, Studer A, Carneiro I, Schellenberg D, et al. Modelling the epidemiological impact of intermittent preventive treatment against malaria in infants. PLoS ONE. 2008;3:e2661.","journal-title":"PLoS ONE"},{"key":"4564_CR20","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1016\/S2542-5196(21)00296-5","volume":"6","author":"E Sherrard-Smith","year":"2022","unstructured":"Sherrard-Smith E, Winskill P, Hamlet A, Ngufor C, N\u2019Guessan R, Guelbeogo MW, et al. Optimising the deployment of vector control tools against malaria: a data-informed modelling study. Lancet Planet Health. 2022;6:e100\u2013109.","journal-title":"Lancet Planet Health"},{"key":"4564_CR21","doi-asserted-by":"publisher","first-page":"e0187680","DOI":"10.1371\/journal.pone.0187680","volume":"12","author":"SS Kiware","year":"2017","unstructured":"Kiware SS, Chitnis N, Tatarsky A, Wu S, Castellanos HMS, Gosling R, et al. Attacking the mosquito on multiple fronts: insights from the Vector Control Optimization Model (VCOM) for malaria elimination. PLoS ONE. 2017;12:e0187680.","journal-title":"PLoS ONE"},{"key":"4564_CR22","doi-asserted-by":"crossref","unstructured":"Eckhoff PA, Wenger EA, Arifin SMN, Madey GR, Collins FH. The EMOD individual-based model. In: Niaz Arifin SM, Nadley GR, Collins FH, editors. Spatial agent-based simulation modeling in public health: design, implementation, and applications for malaria epidemiology. John Wiley & Sons, Inc; 2016. pp. 185\u2013208.","DOI":"10.1002\/9781118964385.ch11"},{"key":"4564_CR23","doi-asserted-by":"publisher","first-page":"fty059","DOI":"10.1093\/femspd\/fty059","volume":"76","author":"A Bershteyn","year":"2018","unstructured":"Bershteyn A, Gerardin J, Bridenbecker D, Lorton CW, Bloedow J, Baker RS, et al. Implementation and applications of EMOD, an individual-based multi-disease modeling platform. Pathog Dis. 2018;76:fty059.","journal-title":"Pathog Dis"},{"key":"4564_CR24","unstructured":"Institute for Disease Modeling. Epidemiological MODeling software (EMOD). 2022. https:\/\/www.idmod.org\/tools. Accessed 28 Jul 2022."},{"key":"4564_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12879-015-0887-y","volume":"15","author":"J Gerardin","year":"2015","unstructured":"Gerardin J, Eckhoff P, Wenger EA. Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination. BMC Infect Dis. 2015;15:144.","journal-title":"BMC Infect Dis"},{"key":"4564_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/inthealth\/ihy025","volume":"10","author":"J Gerardin","year":"2018","unstructured":"Gerardin J, Bertozzi-Villa A, Eckhoff PA, Wenger EA. Impact of mass drug administration campaigns depends on interaction with seasonal human movement. Int Health. 2018;10:252\u20137.","journal-title":"Int Health"},{"key":"4564_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0140-6736(15)00725-4","volume":"387","author":"MA Penny","year":"2016","unstructured":"Penny MA, Verity R, Bever CA, Sauboin C, Galactionova K, Flasche S, et al. Public health impact and cost-effectiveness of the RTS,S\/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2016;387:367\u201375.","journal-title":"Lancet"},{"key":"4564_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s12879-018-3319-y","volume":"18","author":"P Selvaraj","year":"2018","unstructured":"Selvaraj P, Wenger EA, Gerardin J. Seasonality and heterogeneity of malaria transmission determine success of interventions in high-endemic settings: a modeling study. BMC Infect Dis. 2018;18:413.","journal-title":"BMC Infect Dis"},{"key":"4564_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1475-2875-14-6","volume":"14","author":"KA McCarthy","year":"2015","unstructured":"McCarthy KA, Wenger EA, Huynh GH, Eckhoff PA. Calibration of an intrahost malaria model and parameter ensemble evaluation of a pre-erythrocytic vaccine. Malar J. 2015;14:6.","journal-title":"Malar J"},{"key":"4564_CR30","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/S0140-6736(97)02038-2","volume":"349","author":"RW Snow","year":"1997","unstructured":"Snow RW, Omumbo JA, Lowe B, Molyneux CS, Obiero J-O, Palmer A, et al. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet. 1997;349:1650\u20134.","journal-title":"Lancet"},{"key":"4564_CR31","volume-title":"Python 3 reference Manual","author":"G Van Rossum","year":"2009","unstructured":"Van Rossum G, Drake FL. Python 3 reference Manual. Scotts Valley, CA: CreateSpace; 2009. https:\/\/www.python.org\/."},{"key":"4564_CR32","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2022","unstructured":"Core Team R. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022. https:\/\/www.r-project.org\/."},{"key":"4564_CR33","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/bmj.331.7519.727","volume":"331","author":"D Chandramohan","year":"2005","unstructured":"Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, Mensah N, et al. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ. 2005;331:727\u201333.","journal-title":"BMJ"},{"key":"4564_CR34","doi-asserted-by":"publisher","first-page":"e2227","DOI":"10.1371\/journal.pone.0002227","volume":"3","author":"M Cairns","year":"2008","unstructured":"Cairns M, Carneiro I, Milligan P, Owusu-Agyei S, Awine T, Gosling R, et al. Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. PLoS ONE. 2008;3:e2227.","journal-title":"PLoS ONE"},{"key":"4564_CR35","unstructured":"WHO. Regional Office for Africa. Regional Strategic Plan for Immunization 2014\u20132020. World Health Organization. Regional Office for Africa; 2015."},{"key":"4564_CR36","doi-asserted-by":"crossref","unstructured":"Ozodiegwu ID, Ambrose M, Galatas B, Runge M, Nandi A, Okuneye K et al. Application of mathematical modeling to inform national malaria intervention planning in Nigeria. Res Square. 2022.","DOI":"10.21203\/rs.3.rs-2335288\/v1"},{"key":"4564_CR37","volume-title":"A framework for malaria elimination","author":"WHO","year":"2017","unstructured":"WHO. A framework for malaria elimination. Geneva: World Health Organization; 2017."},{"key":"4564_CR38","volume-title":"Nigeria Demographic and Health Survey 2018","author":"Nigeria National Population Commission (NPC) and ICF","year":"2019","unstructured":"Nigeria National Population Commission (NPC) and ICF. Nigeria Demographic and Health Survey 2018. Nigeria, and Rockville, Maryland, USA: NPC and ICF.: Abuja; 2019."},{"key":"4564_CR39","doi-asserted-by":"crossref","unstructured":"Watson OJ, Eaton J, McGowan LD, Gillespie D, rdhs. API Client and Dataset Management for the Demographic and Health Survey (DHS) Data. 2019 https:\/\/CRAN.R-project.org\/package=rdhs.","DOI":"10.32614\/CRAN.package.rdhs"},{"key":"4564_CR40","unstructured":"WorldPop and National Population Commission of Nigeria. Bottom-up gridded population estimates for Nigeria, version 2.0. 17 Nov 2021."},{"key":"4564_CR41","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1475-2875-7-54","volume":"7","author":"RD Gosling","year":"2008","unstructured":"Gosling RD, Ghani AC, Deen JL, von Seidlein L, Greenwood BM, Chandramohan D. Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants? Malar J. 2008;7:54.","journal-title":"Malar J"},{"key":"4564_CR42","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/infdis\/jiac322","volume":"226","author":"GJ Bell","year":"2022","unstructured":"Bell GJ, Goel V, Essone P, Dosoo D, Adu B, Mensah BA, et al. Malaria transmission intensity likely modifies RTS, S\/AS01 efficacy due to a rebound effect in Ghana, Malawi, and Gabon. J Infect Dis. 2022;226:1646\u201356.","journal-title":"J Infect Dis"},{"key":"4564_CR43","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1371\/journal.pmed.0040242","volume":"4","author":"JJ Aponte","year":"2007","unstructured":"Aponte JJ, Menendez C, Schellenberg D, Kahigwa E, Mshinda H, Vountasou P, et al. Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med. 2007;4:e242.","journal-title":"PLoS Med"},{"key":"4564_CR44","doi-asserted-by":"publisher","first-page":"794","DOI":"10.2471\/BLT.15.162172","volume":"94","author":"MC Restrepo-M\u00e9ndez","year":"2016","unstructured":"Restrepo-M\u00e9ndez MC, Barros AJ, Wong KL, Johnson HL, Pariyo G, Fran\u00e7a GV, et al. Inequalities in full immunization coverage: trends in low- and middle-income countries. Bull World Health Organ. 2016;94:794\u2013805.","journal-title":"Bull World Health Organ"},{"key":"4564_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s41182-021-00319-x","volume":"49","author":"SM Fenta","year":"2021","unstructured":"Fenta SM, Biresaw HB, Fentaw KD, Gebremichael SG. Determinants of full childhood immunization among children aged 12\u201323 months in sub-saharan Africa: a multilevel analysis using demographic and Health Survey Data. Trop Med Health. 2021;49:29.","journal-title":"Trop Med Health"},{"key":"4564_CR46","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2458-11-404","volume":"11","author":"LT Fadnes","year":"2011","unstructured":"Fadnes LT, Jackson D, Engebretsen IMS, Zembe W, Sanders D, Sommerfelt H, et al. Vaccination coverage and timeliness in three south african areas: a prospective study. BMC Public Health. 2011;11:404.","journal-title":"BMC Public Health"},{"key":"4564_CR47","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12889-019-6413-1","volume":"19","author":"AE Aghaji","year":"2019","unstructured":"Aghaji AE, Duke R, Aghaji UCW. Inequitable coverage of vitamin A supplementation in Nigeria and implications for childhood blindness. BMC Public Health. 2019;19:282.","journal-title":"BMC Public Health"},{"key":"4564_CR48","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1186\/1471-2458-11-573","volume":"11","author":"A Dicko","year":"2011","unstructured":"Dicko A, Toure SO, Traore M, Sagara I, Toure OB, Sissoko MS, et al. Increase in EPI vaccines coverage after implementation of intermittent preventive treatment of malaria in infant with sulfadoxine -pyrimethamine in the district of Kolokani, Mali: results from a cluster randomized control trial. BMC Public Health. 2011;11:573.","journal-title":"BMC Public Health"},{"key":"4564_CR49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12936-021-03857-1","volume":"20","author":"D Tabiri","year":"2021","unstructured":"Tabiri D, Ou\u00e9draogo JCRP, Nortey PA. Factors associated with malaria vaccine uptake in Sunyani Municipality, Ghana. Malar J. 2021;20:325.","journal-title":"Malar J"},{"key":"4564_CR50","doi-asserted-by":"publisher","first-page":"e0268009","DOI":"10.1371\/journal.pone.0268009","volume":"17","author":"S Darkwa","year":"2022","unstructured":"Darkwa S, de Wildt G, Dalaba M, Vidzro E, Ansah EK. I would have to sell things in order to get the money\u201d: a qualitative exploration of willingness to pay for the RTS,S\/AS01 malaria vaccine in the Volta region, Ghana. PLoS ONE. 2022;17:e0268009.","journal-title":"PLoS ONE"},{"key":"4564_CR51","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/S0140-6736(00)04643-2","volume":"357","author":"D Schellenberg","year":"2001","unstructured":"Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet. 2001;357:1471\u20137.","journal-title":"Lancet"},{"key":"4564_CR52","doi-asserted-by":"publisher","first-page":"e1001689","DOI":"10.1371\/journal.pmed.1001689","volume":"11","author":"V Bigira","year":"2014","unstructured":"Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young ugandan children: a randomized controlled trial. PLoS Med. 2014;11:e1001689.","journal-title":"PLoS Med"},{"key":"4564_CR53","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1128\/AAC.00513-07","volume":"51","author":"FP Mockenhaupt","year":"2007","unstructured":"Mockenhaupt FP, Reither K, Zanger P, Roepcke F, Danquah I, Saad E, et al. Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in Northern Ghana. Antimicrob Agents Chemother. 2007;51:3273\u201381.","journal-title":"Antimicrob Agents Chemother"},{"key":"4564_CR54","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1371\/journal.pmed.0040251","volume":"4","author":"P Bejon","year":"2007","unstructured":"Bejon P, Berkley JA, Mwangi T, Ogada E, Mwangi I, Maitland K, et al. Defining childhood severe falciparum malaria for intervention studies. PLoS Med. 2007;4:e251.","journal-title":"PLoS Med"},{"key":"4564_CR55","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12936-022-04378-1","volume":"21","author":"D Yeboah","year":"2022","unstructured":"Yeboah D, Owusu-Marfo J, Agyeman YN. Predictors of malaria vaccine uptake among children 6\u201324 months in the Kassena Nankana Municipality in the Upper East Region of Ghana. Malar J. 2022;21:339.","journal-title":"Malar J"},{"key":"4564_CR56","doi-asserted-by":"publisher","first-page":"e003217","DOI":"10.1136\/bmjgh-2020-003217","volume":"5","author":"F Amimo","year":"2020","unstructured":"Amimo F, Lambert B, Magit A, Sacarlal J, Hashizume M, Shibuya K. Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in Africa: a systematic analysis of national trends. BMJ Glob Health. 2020;5:e003217.","journal-title":"BMJ Glob Health"},{"key":"4564_CR57","doi-asserted-by":"publisher","first-page":"e1010317","DOI":"10.1371\/journal.pcbi.1010317","volume":"18","author":"JA Flegg","year":"2022","unstructured":"Flegg JA, Humphreys GS, Montanez B, Strickland T, Jacome-Meza ZJ, Barnes KI, et al. Spatiotemporal spread of Plasmodium falciparum mutations for resistance to sulfadoxine-pyrimethamine across Africa, 1990\u20132020. PLoS Comput Biol. 2022;18:e1010317.","journal-title":"PLoS Comput Biol"},{"key":"4564_CR58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/tropicalmed6020075","volume":"6","author":"C Audibert","year":"2021","unstructured":"Audibert C, Tchouatieu A-M. Perception of malaria chemoprevention interventions in infants and children in eight sub-saharan african countries: an end user perspective study. Trop Med Infect Dis. 2021;6:75.","journal-title":"Trop Med Infect Dis"},{"key":"4564_CR59","first-page":"101","volume":"10","author":"B Greenwood","year":"2022","unstructured":"Greenwood B, Schellenberg D. Chemoprevention for the Populations of Malaria Endemic Africa. Dis Basel Switz. 2022;10:101.","journal-title":"Dis Basel Switz"},{"key":"4564_CR60","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12936-022-04115-8","volume":"21","author":"CV Plowe","year":"2022","unstructured":"Plowe CV. Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malar J. 2022;21:104.","journal-title":"Malar J"},{"key":"4564_CR61","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1473-3099(22)00593-X","volume":"23","author":"KB Beshir","year":"2022","unstructured":"Beshir KB, Muwanguzi J, Nader J, Mansukhani R, Traore A, Gamougam K, et al. Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine\u2013pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven african countries: a genomic surveillance study. Lancet Infect Dis. 2022;23:361\u201370.","journal-title":"Lancet Infect Dis"},{"key":"4564_CR62","doi-asserted-by":"publisher","first-page":"e0000262","DOI":"10.1371\/journal.pgph.0000262","volume":"2","author":"F Okumu","year":"2022","unstructured":"Okumu F, Gyapong M, Casamitjana N, Castro MC, Itoe MA, Okonofua F, et al. What Africa can do to accelerate and sustain progress against malaria. PLoS Glob Public Health. 2022;2:e0000262.","journal-title":"PLoS Glob Public Health"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04564-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-023-04564-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04564-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T22:53:56Z","timestamp":1729292036000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-023-04564-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4564"],"URL":"https:\/\/doi.org\/10.1186\/s12936-023-04564-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2710667\/v1","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"19 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}